Three scientists win the Nobel Prize in Medicine for optogenetics — a light-powered brain tool with real treatment potential

The 2026 Nobel Prize in Physiology or Medicine went to Karl Deisseroth (Stanford), Peter Hegemann (Humboldt University), and Georg Nagel (University of Würzburg) for their pioneering work on optogenetics — a technique that uses light to precisely control individual nerve cells in a living brain. The Nobel Assembly called it the dawn of "a new era in neuroscience."

The breakthrough traces back to Hegemann's curiosity about how single-celled green algae swim toward light. He and Nagel identified a protein — channelrhodopsin-2 — that opens an ion channel when hit with blue light, generating an electrical impulse. Deisseroth then harnessed the gene controlling that protein to create a light-controlled switch for neurons in living mice, with the method formally named "optogenetics" in 2006. Beyond the lab, the technique is already being applied clinically — most notably to partially restore vision in patients with retinitis pigmentosa. Researchers are also using it to study schizophrenia, Alzheimer's, Parkinson's, epilepsy, and addiction.

By the Numbers:

• Prize sum: 12 million Swedish kronor (~$1.2 million), shared among the three laureates
• Hegemann, 71, and Nagel, 73, are based in Germany; Deisseroth, 54, is at Stanford in California
• The technique was formally named "optogenetics" in 2006, roughly a decade after Hegemann's initial algae research in the early 1990s

Why it matters: Optogenetics gives scientists an unprecedented, precise way to probe which brain circuits drive behavior and disease — something nearly impossible with prior tools. With clinical applications underway for vision restoration and therapies for autism in development, this Nobel-winning science is moving from bench to bedside faster than many expected.